Google
NRIX — NURIX THERAPEUTICS INC (Healthcare >> Biotechnology)
NRIX FAQ
What is NRIX's ROE?
NURIX THERAPEUTICS INC reports a Return on Equity (ROE) of -61.40%.
What is NRIX's dividend yield?
NURIX THERAPEUTICS INC offers a dividend yield of 0.00%.
What is NRIX's Deepscope Quality Score?
Deepscope rates NRIX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NRIX?
Deepscope's AI Timing Score for NRIX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NRIX belong to?
NURIX THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 15.64
Price
0.00
(0.00%)
Day Change
|
|
|---|
NRIX, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 71 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.64 |
| PBV / Sector |
3.15 / 4.71
|
| Earning Per Share | -3.05 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
38.15 M
GREAT
|
| Average 1W Daily Value |
99.62 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:03 |
| Symbol | NRIX |
| Name | NURIX THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 103.41 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,513.86 / 8,889.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone: 415 660 5320
Website: https://www.nurixtx.com
Employees: 317
Sector: Healthcare >> Biotechnology
Description: Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
